{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:27:22Z","timestamp":1772252842368,"version":"3.50.1"},"reference-count":80,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>COVID-19 was declared a pandemic in March 2020. The knowledge of COVID-19 pathophysiology soon provided a strong rationale for the early use of both anti-inflammatory and antithrombotic drugs; however, its evidence was slowly and partially incorporated into institutional guidelines. The unmet needs of COVID-19 outpatients were taken care of by networks of physicians and researchers. We analyse the characteristics, management and outcomes in COVID-19 outpatients who were taken care of by physicians within the IppocrateOrg Association. In this observational retrospective study, volunteering doctors provided data on 392 COVID-19 patients. The mean age of patients was 48.5 years (range: 0.5\u201397), and patients were taken care of in COVID-19 stage 0 (15.6%), stage 1 (50.0%), stage 2a (28.8%) and stage 2b (5.6%). Many patients were overweight (26%) or obese (11.5%), with chronic comorbidities (34.9%), mainly cardiovascular (23%) and metabolic (13.3%). The most frequently prescribed drugs included: vitamins and supplements (98.7%), aspirin (66.1%), antibiotics (62%), glucocorticoids (41.8%), hydroxychloroquine (29.6%), enoxaparin (28.6%), colchicine (8.9%), oxygen therapy (6.9%), and ivermectin (2.8%). Hospitalization occurred in 5.8% of cases, mainly in stage 2b (27.3%). A total of 390 patients (99.6%) recovered; one patient was lost at follow up, and one patient died after hospitalization. This is the first real-world study describing the behaviours of physicians caring for COVID-19 outpatients, and the outcomes of COVID-19 early treatment. The lethality in this cohort was 0.2%, while overall, and over the same period, the COVID-19 lethality in Italy was over 3%. The drug use described in this study appears effective and safe. The present evidence should be carefully considered by physicians and political decision makers.<\/jats:p>","DOI":"10.3390\/jcm11206138","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:58:51Z","timestamp":1666141131000},"page":"6138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6978-7775","authenticated-orcid":false,"given":"Marco","family":"Cosentino","sequence":"first","affiliation":[{"name":"Center for Research in Medical Pharmacology, University of Insubria, 21100 Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Vernocchi","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-9138","authenticated-orcid":false,"given":"Stefano","family":"Martini","sequence":"additional","affiliation":[{"name":"Center for Research in Medical Pharmacology, University of Insubria, 21100 Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Marino","sequence":"additional","affiliation":[{"name":"Center for Research in Medical Pharmacology, University of Insubria, 21100 Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Allasino","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonietta","family":"B\u00e0lzola","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Burigana","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Dallari","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Servo Florio","family":"Pagano","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palma","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Rango","sequence":"additional","affiliation":[{"name":"IppocrateOrg Association, Via Canova 15, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of IppocrateOrg Association Working Group for the Early Outpatient Treatment of COVID-19","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_2","unstructured":"(2022, October 03). World Health Organization WHO Announces COVID-19 Outbreak a Pandemic. Available online: https:\/\/www.euro.who.int\/en\/health-topics\/health-emergencies\/coronavirus-covid-19\/news\/news\/2020\/3\/who-announces-covid-19-outbreak-a-pandemic."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: What Next?","volume":"395","author":"Remuzzi","year":"2020","journal-title":"Lancet"},{"key":"ref_4","unstructured":"(2022, October 03). Ministero Della Salute CIRCOLARE Del 08\/04\/2020 Indicazioni Emergenziali Connesse Ad Epidemia COVID-19 Riguardanti Il Settore Funebre, Cimiteriale e Di Cremazione, Available online: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2020&codLeg=73832&parte=1%20&serie=null."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1473-3099(20)30434-5","article-title":"Pulmonary Post-Mortem Findings in a Series of COVID-19 Cases from Northern Italy: A Two-Centre Descriptive Study","volume":"20","author":"Carsana","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","unstructured":"Ministero della Salute CIRCOLARE Del 26\/04\/2021 (2022, October 03). Gestione Domiciliare Dei Pazienti Con Infezione Da SARS-CoV2 Aggiornata al 26 Aprile 2021, Available online: https:\/\/www.trovanorme.salute.gov.it\/norme\/renderNormsanPdf?anno=2021&codLeg=80056&parte=1%20&serie=null."},{"key":"ref_7","unstructured":"(2021, September 21). AIFA Idrossiclorochina Nella Terapia dei Pazienti Adulti con COVID-19\u2014Update del 22 Luglio 2020, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/1123276\/idrossiclorochina_22.07.2020.pdf\/764add8f-f08f-0e26-df75-952986e54b8b."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: A clinical\u2013therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transpl."},{"key":"ref_9","first-page":"8606","article-title":"Three Critical Clinicobiological Phases of the Human SARS-Associated Coronavirus Infections","volume":"24","author":"Turk","year":"2020","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ccell.2020.10.006","article-title":"COVID-19: Staging of a New Disease","volume":"38","author":"Pujadas","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_11","unstructured":"Rango, M. (2021). Guarire Il COVID-19 a Casa: Manuale per Terapia Domiciliare Personalizzata, Independently published."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106214","DOI":"10.1016\/j.ijantimicag.2020.106214","article-title":"COVID-19 outpatients: Early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: A retrospective case series study","volume":"56","author":"Derwand","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.31083\/j.rcm.2020.04.264","article-title":"Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)","volume":"21","author":"McCullough","year":"2020","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"E693","DOI":"10.9778\/cmajo.20210069","article-title":"Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: A randomized controlled trial","volume":"9","author":"Schwartz","year":"2021","journal-title":"CMAJ Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e216468","DOI":"10.1001\/jamanetworkopen.2021.6468","article-title":"Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial","volume":"4","author":"Reis","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): A phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.2021.11517","article-title":"Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients with SARS-CoV-2 Infection: A Randomized Clinical Trial","volume":"326","author":"Oldenburg","year":"2021","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S2213-2600(21)00263-0","article-title":"Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): An open-label, randomised trial","volume":"9","author":"Hinks","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_19","first-page":"1","article-title":"Efficacy of the Use of Mefenamic Acid Combined with Standard Medical Care vs. Standard Medical Care Alone for the Treatment of COVID-19: A Randomized Double-Blind Placebo-Controlled Trial","volume":"49","author":"Melnikov","year":"2022","journal-title":"J. Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","article-title":"Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial","volume":"182","author":"Clemency","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e068060","DOI":"10.1136\/bmj-2021-068060","article-title":"Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial","volume":"375","author":"Ezer","year":"2021","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jac\/dkaa501","article-title":"Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: A double-blind, randomized controlled trial","volume":"76","author":"Roozbeh","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early Convalescent Plasma for High-Risk Outpatients with Covid-19","volume":"385","author":"Korley","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: A phase 2, placebo-controlled randomised trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1055\/a-1414-5216","article-title":"Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial","volume":"121","author":"Ochoa","year":"2021","journal-title":"Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e210369","DOI":"10.1001\/jamanetworkopen.2021.0369","article-title":"Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial","volume":"4","author":"Thomas","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"106428","DOI":"10.1016\/j.ijantimicag.2021.106428","article-title":"Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: A randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance","volume":"58","author":"Rodrigues","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e935379","DOI":"10.12659\/MSM.935379","article-title":"Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home within 3 Days or after 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021","volume":"28","author":"Fazio","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100941","DOI":"10.1016\/j.eclinm.2021.100941","article-title":"A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study","volume":"37","author":"Suter","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.amjmed.2020.07.003","article-title":"Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection","volume":"134","author":"McCullough","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_34","first-page":"1","article-title":"I-MASK+\u2014Prevention & Early Outpatient Treatment Protocol for COVID-19","volume":"19","author":"Alliance","year":"2022","journal-title":"Version"},{"key":"ref_35","unstructured":"The Frohman Foundation (2022, October 03). Outpatient COVID-19 Treatment to Prevent Severe Disease. Available online: https:\/\/thefrohmanfoundation.org\/research\/covid-19-treatment\/outpatient-covid-19-treatment-to-prevent-severe-disease\/."},{"key":"ref_36","first-page":"15","article-title":"Il case fatality rate dell\u2019infezione SARS-CoV-2 a livello regionale e attraverso le differenti fasi dell\u2019epidemia in Italia. Versione del 20 gennaio 2021","volume":"51","author":"Fabiani","year":"2021","journal-title":"Ist. Super. Sanit\u00e0"},{"key":"ref_37","unstructured":"Task Force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica, Istituto Superiore di Sanit\u00e0 Epidemia COVID-19 (2022, October 03). Aggiornamento Nazionale: 28 Aprile 2021. Available online: https:\/\/www.epicentro.iss.it\/coronavirus\/bollettino\/Bollettino-sorveglianza-integrata-COVID-19_28-aprile-2021.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.31083\/j.rcm2203116","article-title":"Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients","volume":"22","author":"Million","year":"2021","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bae, M., and Kim, H. (2020). Mini-Review on the Roles of Vitamin C, Vitamin D, and Selenium in the Immune System against COVID-19. Molecules, 25.","DOI":"10.3390\/molecules25225346"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Grant, W.B., Lahore, H., McDonnell, S.L., Baggerly, C.A., French, C.B., Aliano, J.L., and Bhattoa, H.P. (2020). Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients, 12.","DOI":"10.20944\/preprints202003.0235.v2"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12967-020-02488-5","article-title":"The Importance of Vitamin d Metabolism as a Potential Prophylactic, Immunoregulatory and Neuroprotective Treatment for COVID-19","volume":"18","author":"Xu","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_42","unstructured":"(2022, October 17). Vitamin D for COVID-19: Real-Time Analysis of All 315 Studies. Available online: https:\/\/c19vitamind.com\/."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Holford, P., Carr, A.C., Jovic, T.H., Ali, S.R., Whitaker, I.S., Marik, P.E., and Smith, A.D. (2020). Vitamin C\u2014An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. Nutrients, 12.","DOI":"10.20944\/preprints202010.0407.v2"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3389\/fimmu.2020.01451","article-title":"Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)","volume":"11","author":"Berrill","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_45","unstructured":"(2022, October 17). Vitamin C for COVID-19: Real-Time Analysis of All 86 Studies. Available online: https:\/\/c19early.com\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3389\/fimmu.2020.01712","article-title":"The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis","volume":"11","author":"Wessels","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_47","first-page":"17","article-title":"Zinc and Respiratory Tract Infections: Perspectives for COVID-19 (Review)","volume":"46","author":"Skalny","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"ref_48","unstructured":"(2022, October 17). Zinc for COVID-19: Real-Time Analysis of All 90 Studies. Available online: https:\/\/c19zinc.com\/."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bellavite, P., and Donzelli, A. (2020). Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. Antioxidants, 9.","DOI":"10.20944\/preprints202006.0321.v1"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/ptr.6893","article-title":"Potential Roles of Medicinal Plants for the Treatment of Viral Diseases Focusing on COVID-19: A Review","volume":"35","author":"Adhikari","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ptr.6887","article-title":"A Role for Quercetin in Coronavirus Disease 2019 (COVID-19)","volume":"35","author":"Derosa","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_52","unstructured":"(2022, October 17). Quercetin for COVID-19: Real-Time Analysis of All 22 Studies. Available online: https:\/\/c19quercetin.com\/."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3892\/etm.2020.9402","article-title":"Lactoferrin for the Treatment of COVID-19 (Review)","volume":"20","author":"Wang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106118","DOI":"10.1016\/j.ijantimicag.2020.106118","article-title":"Lactoferrin as Potential Preventative and Adjunct Treatment for COVID-19","volume":"56","author":"Chang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s11739-020-02383-3","article-title":"Potential New Treatment Strategies for COVID-19: Is There a Role for Bromhexine as Add-on Therapy?","volume":"15","author":"Depfenhart","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/ptr.7008","article-title":"Botanical Drugs and Supplements Affecting the Immune Response in the Time of COVID-19: Implications for Research and Clinical Practice","volume":"35","author":"Brendler","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_57","first-page":"e2020008","article-title":"Natural Compounds as Inhibitors of SARS-CoV-2 Endocytosis: A Promising Approach against COVID-19","volume":"91","author":"Kiani","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/0022034520967933","article-title":"Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2","volume":"100","author":"Carrouel","year":"2021","journal-title":"J. Dent. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/1440-1681.13354","article-title":"A Role for Retinoids in the Treatment of COVID-19?","volume":"47","author":"Trasino","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2204","article-title":"Mega Doses of Retinol: A Possible Immunomodulation in Covid-19 Illness in Resource-Limited Settings","volume":"31","author":"Midha","year":"2021","journal-title":"Rev. Med. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107613","DOI":"10.1016\/j.pharmthera.2020.107613","article-title":"Therapeutic Potential of Resveratrol against Emerging Respiratory Viral Infections","volume":"214","author":"Filardo","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s40265-020-01365-1","article-title":"Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19?","volume":"80","author":"Bianconi","year":"2020","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10760296211014592","DOI":"10.1177\/10760296211014592","article-title":"Could Low Doses Acetylsalicylic Acid Prevent Thrombotic Complications in COVID-19 Patients?","volume":"27","author":"Cacciapuoti","year":"2021","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_64","unstructured":"(2022, October 17). Aspirin for COVID-19: Real-Time Analysis of All 61 Studies. Available online: https:\/\/c19aspirin.com\/."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1097\/MJT.0000000000001377","article-title":"Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19","volume":"28","author":"Kory","year":"2021","journal-title":"Am. J. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1097\/MJT.0000000000001443","article-title":"Ivermectin, A Reanalysis of the Data","volume":"28","author":"Marik","year":"2021","journal-title":"Am. J. Ther."},{"key":"ref_67","unstructured":"(2022, October 17). Ivermectin for COVID-19: Real-Time Analysis of All 185 Studies. Available online: https:\/\/c19ivermectin.com\/."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"106240","DOI":"10.1016\/j.ijantimicag.2020.106240","article-title":"Effect of Hydroxychloroquine and Azithromycin on SARS-CoV-2 Clearance in COVID-19 Patients, a Meta-Analysis","volume":"57","author":"Million","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.4103\/ijph.IJPH_496_20","article-title":"Hydroxychloroquine as Prophylaxis or Treatment for COVID-19: What Does the Evidence Say?","volume":"64","author":"Nina","year":"2020","journal-title":"Indian J. Public Health"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/postgradmedj-2020-137785","article-title":"Hydroxychloroquine and COVID-19","volume":"96","author":"Sinha","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"ref_71","unstructured":"(2022, October 17). HCQ for COVID-19: Real-Time Analysis of All 444 Studies. Available online: https:\/\/c19hcq.com\/."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/14787210.2020.1813024","article-title":"Azithromycin in the Treatment of COVID-19: A Review","volume":"19","author":"Horcajada","year":"2021","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1753466620951053","DOI":"10.1177\/1753466620951053","article-title":"Doxycycline Treatment of High-Risk COVID-19-Positive Patients with Comorbid Pulmonary Disease","volume":"14","author":"Yates","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/annrheumdis-2020-219174","article-title":"Anti-Inflammatory Therapy for COVID-19 Infection: The Case for Colchicine","volume":"80","author":"Reyes","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","unstructured":"(2022, October 17). Colchicine for COVID-19: Real-Time Analysis of All 39 Studies. Available online: https:\/\/c19colchicine.com\/."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"579886","DOI":"10.3389\/fphar.2020.579886","article-title":"Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence","volume":"11","author":"Drago","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s13054-020-03000-7","article-title":"Prevention of Thrombotic Risk in Hospitalized Patients with COVID-19 and Hemostasis Monitoring","volume":"24","author":"Susen","year":"2020","journal-title":"Crit. Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2147\/TCRM.S273700","article-title":"N-Acetylcysteine to Combat COVID-19: An Evidence Review","volume":"16","author":"Shi","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"610132","DOI":"10.3389\/fmolb.2020.610132","article-title":"The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic","volume":"7","author":"Aigner","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/a-1300-2550","article-title":"The Role of Glucocorticoids in the Management of COVID-19","volume":"53","author":"Alexaki","year":"2021","journal-title":"Horm. Metab. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:56:46Z","timestamp":1760144206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":80,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11206138"],"URL":"https:\/\/doi.org\/10.3390\/jcm11206138","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.04.22273356","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]}}}